Who are Brenzavvy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Jardiance, B55R1 and B55R2, Ertugliflozin 5 mg, CDobi, Ertugliflozin 15 mg, senfrol monotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bexagliflozin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Brenzavvy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brenzavvy (BEXAGLIFLOZIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sodium-Glucose Cotransporter 2 Inhibitor [EPC]. Area: Metabolic.

marketed Sodium-Glucose Cotransporter 2 Inhibitor [EPC] SGLT2 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Brenzavvy (BEXAGLIFLOZIN) — Theracosbio. Bexagliflozin inhibits SGLT2 to reduce renal glucose reabsorption and increase urinary glucose excretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Brenzavvy TARGET	BEXAGLIFLOZIN	Theracosbio	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2023-01-01
Jardiance	empagliflozin	Boehringer Ingelheim	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2014-01-01
B55R1 and B55R2	B55R1 and B55R2	AJU Pharm Co., Ltd.	marketed	SGLT2 inhibitor	SGLT2
Ertugliflozin 5 mg	ertugliflozin-5-mg	Pfizer	marketed	SGLT2 inhibitor	SGLT2
CDobi	CDobi	Services Hospital, Lahore	marketed	SGLT2 inhibitor	SGLT2
Ertugliflozin 15 mg	ertugliflozin-15-mg	Pfizer	marketed	SGLT2 inhibitor	SGLT2
senfrol monotherapy	senfrol monotherapy	Peking University Third Hospital	marketed	SGLT2 inhibitor	SGLT2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sodium-Glucose Cotransporter 2 Inhibitor [EPC] class)

· 1 drug in this class
AJANTA PHARMA LTD · 1 drug in this class
AstraZeneca · 1 drug in this class
Boehringer Ingelheim · 1 drug in this class
Lexicon Pharms Inc · 1 drug in this class
Theracosbio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brenzavvy — Competitive Intelligence Brief. https://druglandscape.com/ci/bexagliflozin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing